Evidence map›Paper›PMID 38317930›Full record

ReviewHeliyon2024

MiRNA in cervical cancer: Diagnosis to therapy: Systematic review.

Hiwot Tezera Endale, Yitbarek Fantahun Mariye, Habtu Kifle Negash, Fethiya Seid Hassen, Wastina Bitewlign Asrat, Tiget Ayelgn Mengstie, Winta Tesfaye

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. MicroRNA Gets a Mighty Award.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hiwot Tezera EndaleDepartment of Biochemistry, School of Medicine, College of Medicine & Health Sciences, University of Gondar, Ethiopia.
Yitbarek Fantahun MariyeDepartment of Obstetrics & Gynecology, School of Medicine, College of Medicine & Health Sciences, Addis Ababa University, Ethiopia.
Habtu Kifle NegashDepartment of Human Anatomy, School of Medicine, College of Medicine & Health Sciences, University of Gondar, Ethiopia.
Fethiya Seid HassenDepartment of Biochemistry, School of Medicine, College of Medicine & Health Sciences, University of Gondar, Ethiopia.
Wastina Bitewlign AsratDepartment of Biochemistry, School of Medicine, College of Medicine & Health Sciences, University of Gondar, Ethiopia.
Tiget Ayelgn MengstieDepartment of Biochemistry, School of Medicine, College of Medicine & Health Sciences, University of Gondar, Ethiopia.
Winta TesfayeDepartment of Human Physiology, School of Medicine, College of Medicine & Health Sciences, University of Gondar, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancers are one of the most public health problems worldwide. Among them, cervical cancer (CC) is the fourth most prevalent cancer with 604 000 new cases and 342 000 deaths. Mostly, it is associated with Human papillomavirus (HPV). It has been caused by the aggregation of genetic and epigenetic modifications in cervical epithelial cells. Although genetic mutations are given great attention for the carcinogenesis of CC, epigenetic changes have emerged as a hotspot area for CC biomarkers research with great implications for early diagnosis, prognosis, and treatment response prediction of the disease. Recently, there are several studies focused on miRNAs as biomarkers of cervical cancer. However, the precise function of miRNAs in the development of cervical cancer is not still completely understood, particularly when it comes to unconventional sampling materials like cervical mucus and plasma serum. Hence, this review article will give a summary of the miRNAs profiles that emerge at different stages of cervical cancer progression and their downstream effects on target genes and associated signaling pathways. Finally, these results may provide insight into the use of miRNAs as biomarkers for the prediction or diagnosis of cervical cancer or the development of miRNA-based therapeutics against cervical cancer.

Indexed as

BiomarkerCervical cancerMetastasismiRNAsTherapeutics

Identifiers

PMID38317930
PMCPMC10839805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.